BRWA
KERX

B. Riley Wealth Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

B. Riley Wealth Advisors’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-3,050
Closed -$43 – 2360
2014
Q4 		$43 Buy
+3,050
New +$47.3K ﹤0.01% 2176
2014
Q3 		– Sell
-1,500
Closed -$23.1K – 2200
2014
Q2 		$23.1K Sell
1,500
-4,850
-76% -$68.7K 0.01% 1407
2014
Q1 		$108K Buy
6,350
+2,032
+47% +$30.7K 0.03% 596
2013
Q4 		$56K Buy
+4,318
New +$51.6K 0.02% 652

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

B. Riley Wealth Advisors's KERX Position: Q1 2015 in Review

B. Riley Wealth Advisors sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2015, closing a stake of 3,050 shares — an estimated $43 sold.

B. Riley Wealth Advisors first reported a position in KERX in Q4 2013 and held it in 4 quarters. The position peaked at $108K in Q1 2014. 157 funds tracked by Wall St. Rank hold KERX as of Q1 2015.

  • B. Riley Wealth Advisors reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2015 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 3,050 Keryx Biopharmaceuticals Inc shares in Q1 2015, an estimated $43.
  • B. Riley Wealth Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q4 2013 and held it in 4 quarters.
  • B. Riley Wealth Advisors's Keryx Biopharmaceuticals Inc position peaked at $108K in Q1 2014.
  • 157 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2015.

Based on B. Riley Wealth Advisors's 13F filing for Q1 2015, filed 14 May 2015.